MetaVia Inc. (NASDAQ:MTVA) Short Interest Up 729.1% in January

MetaVia Inc. (NASDAQ:MTVA) saw a significant growth in short interest during the month of January. As of January 15th, there was short interest totaling 163,195 shares, a growth of 729.1% from the December 31st total of 19,683 shares. Based on an average trading volume of 234,028 shares, the short-interest ratio is presently 0.7 days. Currently, 7.5% of the company’s stock are sold short. Currently, 7.5% of the company’s stock are sold short. Based on an average trading volume of 234,028 shares, the short-interest ratio is presently 0.7 days.

Institutional Trading of MetaVia

An institutional investor recently raised its position in MetaVia stock. SG Americas Securities LLC grew its position in MetaVia Inc. (NASDAQ:MTVA) by 44.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 60,386 shares of the company’s stock after acquiring an additional 18,506 shares during the period. SG Americas Securities LLC owned about 0.25% of MetaVia worth $57,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 1.37% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MetaVia in a research report on Monday, December 22nd. Wall Street Zen upgraded shares of MetaVia from a “sell” rating to a “hold” rating in a research note on Saturday, January 17th. Finally, HC Wainwright lifted their price target on MetaVia from $12.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, MetaVia currently has an average rating of “Hold” and an average target price of $36.50.

MetaVia Trading Down 9.6%

MTVA traded down $0.25 during midday trading on Wednesday, hitting $2.35. 282,187 shares of the company were exchanged, compared to its average volume of 286,112. The company’s 50 day simple moving average is $7.44 and its 200 day simple moving average is $8.47. The firm has a market capitalization of $5.17 million, a price-to-earnings ratio of -0.28 and a beta of 0.27. MetaVia has a 1-year low of $2.33 and a 1-year high of $23.10.

MetaVia (NASDAQ:MTVA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($1.54) earnings per share for the quarter, beating the consensus estimate of ($2.86) by $1.32. On average, equities analysts anticipate that MetaVia will post -3.9 EPS for the current year.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.